Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer

Zhang,Wei; Wang,Sumei; Wang,Qi; Yang,Zhijun; Pan,Zhongmian; Li,Li

doi:10.3892/or.2014.2967

Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer

Authors:
- Wei Zhang
- Sumei Wang
- Qi Wang
- Zhijun Yang
- Zhongmian Pan
- Li Li
View Affiliations

Affiliations: Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: January 8, 2014 https://doi.org/10.3892/or.2014.2967
Pages: 1334-1342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cysteine cathepsins (CTSs) are involved in the degradation and remodeling of the extracellular matrix and are associated with cellular transformation, differentiation, motility and adhesion in cancer development. Previous studies indicate that CTSs may be involved in ovarian cancer invasion and metastasis. However, due to the lack of large sample clinical studies and direct experimental evidence for the relationship between the expression of CTSs and invasion and metastasis, the diagnostic and prognostic value of CTSs in ovarian cancer progression has not been elucidated. In the present study, we observed that expression levels of CTSB, CTSL and CC in malignant ovarian tumors were significantly higher than the expression levels in benign tumors and normal ovarian tissues, yet their associations with clinicopathological features varied. In particular, CTSL was related to lymph node metastasis, CC was related to liver metastasis and omental metastasis, and CTSB and CTSL expression levels were found to be independent prognostic factors in ovarian cancer. Further study indicated that the serum level of CTSL was significantly higher in patients with ovarian malignant tumors than the levels in benign tumors and healthy controls, and the levels were elevated in low grade and advanced stage compared to the levels in high grade and early stage disease, suggesting that the serum level of CTSL may be a useful serum marker for the diagnosis of ovarian cancer. Furthermore, the expression of CTSL in ovarian cancer cells can greatly enhance the ability of cell invasion and metastasis, although no change was observed for cell adhesion. Taken together, we demonstrated that the overexpression of CTSL is involved in tumor invasion and metastasis, and the CTSL level in serum may be a marker for invasion and metastasis in ovarian cancer.

View Figures

View References

1	Jemal A, Thomas A, Murray T and Thun M: Cancer statistics, 2002. CA Cancer J Clin. 52:23–47. 2002. View Article : Google Scholar
2	Murdoch WJ, Van Kirk EA and Alexander BM: DNA damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med (Maywood). 230:429–433. 2005.PubMed/NCBI
3	Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macri A, Virzi S, Puccio F, Ravenda PS and Kusamura S: Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 37:4–9. 2011. View Article : Google Scholar
4	Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, Brown R, DeFazio A and Chenevix-Trench G: ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 14:5594–5601. 2008. View Article : Google Scholar
5	Turk V, Turk B and Turk D: Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20:4629–4633. 2001. View Article : Google Scholar : PubMed/NCBI
6	Athanassiadou P, Sakellariou V, Petrakakou E, Athanassiades P, Zerva C, Liossi A and Michalas S: Cathepsin D immunoreactivity in ovarian cancer: correlation with prognostic factors. Pathol Oncol Res. 4:103–107. 1998. View Article : Google Scholar : PubMed/NCBI
7	Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M and Miyakawa I: Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72–4. Gynecol Oncol. 56:357–361. 1995.PubMed/NCBI
8	Kolwijck E, Kos J, Obermajer N, Span PN, Thomas CM, Massuger LF and Sweep FC: The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. Eur J Clin Invest. 40:591–599. 2010. View Article : Google Scholar : PubMed/NCBI
9	Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A and Suzumori K: The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol. 92:881–886. 2004. View Article : Google Scholar : PubMed/NCBI
10	Jedeszko C and Sloane BF: Cysteine cathepsins in human cancer. Biol Chem. 385:1017–1027. 2004. View Article : Google Scholar : PubMed/NCBI
11	Gocheva V and Joyce JA: Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 6:60–64. 2007. View Article : Google Scholar : PubMed/NCBI
12	Mohamed MM and Sloane BF: Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 6:764–775. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G and Van Noorden CJ: Cathepsin L, target in cancer treatment? Life Sci. 86:225–233. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yan S, Sameni M and Sloane BF: Cathepsin B and human tumor progression. Biol Chem. 379:113–123. 1998.PubMed/NCBI
15	Lah TT and Kos J: Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem. 379:125–130. 1998.PubMed/NCBI
16	Rao JS: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 3:489–501. 2003. View Article : Google Scholar : PubMed/NCBI
17	Szpaderska AM and Frankfater A: An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res. 61:3493–3500. 2001.PubMed/NCBI
18	Premzl A, Zavasnik-Bergant V, Turk V and Kos J: Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res. 283:206–214. 2003. View Article : Google Scholar
19	Scorilas A, Fotiou S, Tsiambas E, Yotis J, Kotsiandri F, Sameni M, Sloane BF and Talieri M: Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients. Biol Chem. 383:1297–1303. 2002. View Article : Google Scholar : PubMed/NCBI
20	Wang M, Tang J, Liu S, Yoshida D and Teramoto A: Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol. 71:3–7. 2005. View Article : Google Scholar : PubMed/NCBI
21	He X, Brenchley PE, Jayson GC, Hampson L, Davies J and Hampson IN: Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res. 64:3928–3933. 2004. View Article : Google Scholar : PubMed/NCBI
22	Ricciardelli C and Rodgers RJ: Extracellular matrix of ovarian tumors. Semin Reprod Med. 24:270–282. 2006. View Article : Google Scholar : PubMed/NCBI
23	Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ and Kjaer SK: Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the ‘MALOVA’ ovarian cancer study. Oncol Rep. 18:1051–1059. 2007.PubMed/NCBI
24	Falcetta F, Lupi M, Colombo V and Ubezio P: Dynamic rendering of the heterogeneous cell response to anticancer treatments. PLoS Comput Biol. 9:e10032932013. View Article : Google Scholar : PubMed/NCBI
25	Siewinski M, Saleh Y, Gryboc M, Murawski M, Ekonjo GB, Ziolkowski P, Janocha A and Symonowicz K: Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E. J Exp Ther Oncol. 4:189–193. 2004.PubMed/NCBI
26	Warwas M, Haczynska H, Gerber J and Nowak M: Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem. 35:301–304. 1997.PubMed/NCBI
27	Kolwijck E, Massuger LF, Thomas CM, Span PN, Krasovec M, Kos J and Sweep FC: Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. J Cancer Res Clin Oncol. 136:771–778. 2010. View Article : Google Scholar : PubMed/NCBI
28	Epelman M, Chikwava KR, Chauvin N and Servaes S: Imaging of pediatric ovarian neoplasms. Pediatr Radiol. 41:1085–1099. 2011. View Article : Google Scholar : PubMed/NCBI
29	Levicar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J, Pilkington GJ and Lah TT: Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther. 10:141–151. 2003. View Article : Google Scholar : PubMed/NCBI
30	Yang Z and Cox JL: Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int. 7:82007. View Article : Google Scholar : PubMed/NCBI